A Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy in the Treatment of Enthesitis at the Achilles Tendon up to 1 Year in Adult Patients With Active Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA) (ACHILLES)

Trial Profile

A Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy in the Treatment of Enthesitis at the Achilles Tendon up to 1 Year in Adult Patients With Active Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA) (ACHILLES)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Musculoskeletal disorders; Psoriatic arthritis; Spondylarthritis
  • Focus Therapeutic Use
  • Acronyms ACHILLES
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 25 May 2017 This trial has been completed in Czech Republic, according to European Clinical Trials Database.
    • 07 Apr 2017 Planned End Date changed from 1 Feb 2019 to 29 Mar 2019.
    • 07 Apr 2017 Planned primary completion date changed from 1 Feb 2019 to 29 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top